$BFNH
BIOFORCE NANOSCIENCES HOLDINGS, INC.

2021 Q3 Form 10-Q Financial Statement

#000109181821000099 Filed on July 29, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $113.9K $122.3K $126.7K
YoY Change -3.44% -3.46% 1458.55%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $113.9K $122.3K $126.7K
YoY Change -3.44% -3.47% 1460.47%
Operating Profit -$113.9K -$122.3K -$126.7K
YoY Change -3.44% -3.47% 1664.76%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$113.9K -$122.3K -$126.7K
YoY Change -3.44% -3.46% 1664.76%
Income Tax
% Of Pretax Income
Net Earnings -$113.9K -$122.3K -$126.7K
YoY Change -3.44% -3.47% 1664.76%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share -$3.890K -$4.179K -$8.297K
COMMON SHARES
Basic Shares Outstanding 29.27M shares 29.27M shares
Diluted Shares Outstanding 29.27M shares

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $27.31K $27.31K $39.87K
YoY Change -31.5% -31.5% -2.68%
Cash & Equivalents $27.31K $27.31K $39.87K
Short-Term Investments
Other Short-Term Assets $70.00 $100.00 $2.950K
YoY Change -96.61%
Inventory
Prepaid Expenses $100.00
Receivables
Other Receivables
Total Short-Term Assets $27.38K $27.41K $42.82K
YoY Change -31.33% -36.0% -8.76%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $27.38K $27.41K $42.82K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $27.38K $27.41K $42.82K
YoY Change -31.33% -36.0% -8.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $440.00 $1.030K $0.00
YoY Change -100.0%
Accrued Expenses $644.8K $539.0K $114.9K
YoY Change 191.5% 369.28%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $768.5K $654.7K $162.2K
YoY Change 177.24% 303.54% 3131.87%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $768.5K $654.7K $162.2K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $768.5K $654.7K $162.2K
YoY Change 177.24% 303.54% 3131.87%
SHAREHOLDERS EQUITY
Retained Earnings -$159.4M
YoY Change
Common Stock $158.8M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$741.2K -$627.3K -$119.4K
YoY Change
Total Liabilities & Shareholders Equity $27.38K $27.41K $42.82K
YoY Change -31.33% -36.0% -8.76%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$113.9K -$122.3K -$126.7K
YoY Change -3.44% -3.47% 1664.76%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$8.680K -$27.70K -$20.78K
YoY Change 0.46% 33.3% 324.95%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.680K 23.17K 13.78K
YoY Change 0.46% 68.14% 28.19%
NET CHANGE
Cash From Operating Activities -8.680K -27.70K -20.78K
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 8.680K 23.17K 13.78K
Net Change In Cash 0.000 -4.530K -7.000K
YoY Change -35.29% -219.45%
FREE CASH FLOW
Cash From Operating Activities -$8.680K -$27.70K -$20.78K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Entity Registrant Name
EntityRegistrantName
BIOFORCE NANOSCIENCES HOLDINGS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
74-3078125
dei Entity Address Address Line1
EntityAddressAddressLine1
2020 General Booth Blvd.
dei Entity Central Index Key
EntityCentralIndexKey
0001310488
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Entity Address Address Line2
EntityAddressAddressLine2
Unit 230
dei Entity Address City Or Town
EntityAddressCityOrTown
Virginia Beach
dei Entity Address State Or Province
EntityAddressStateOrProvince
VA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
23454
dei City Area Code
CityAreaCode
757
dei Local Phone Number
LocalPhoneNumber
306-6090
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29271755 shares
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27305 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39865 USD
CY2021Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
100 USD
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
27405 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
39865 USD
CY2021Q2 us-gaap Assets
Assets
27405 USD
CY2020Q4 us-gaap Assets
Assets
39865 USD
CY2021Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1032 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5090 USD
CY2021Q2 us-gaap Accrued Salaries Current And Noncurrent
AccruedSalariesCurrentAndNoncurrent
539017 USD
CY2020Q4 us-gaap Accrued Salaries Current And Noncurrent
AccruedSalariesCurrentAndNoncurrent
327517 USD
CY2021Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
114658 USD
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
67166 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
654707 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
399773 USD
CY2021Q2 us-gaap Liabilities
Liabilities
654707 USD
CY2020Q4 us-gaap Liabilities
Liabilities
399773 USD
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29271755 shares
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29271755 shares
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
29272 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
29272 USD
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
158781127 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
158781127 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-159437701 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-159170307 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-627302 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-359908 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27405 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
39865 USD
CY2020Q2 us-gaap Cost Of Revenue
CostOfRevenue
USD
us-gaap Cost Of Revenue
CostOfRevenue
USD
CY2020Q2 us-gaap Revenues
Revenues
USD
us-gaap Revenues
Revenues
USD
CY2021Q2 us-gaap Gross Profit
GrossProfit
USD
CY2020Q2 us-gaap Gross Profit
GrossProfit
USD
us-gaap Gross Profit
GrossProfit
USD
us-gaap Gross Profit
GrossProfit
USD
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
122315 USD
us-gaap Operating Expenses
OperatingExpenses
267394 USD
us-gaap Operating Expenses
OperatingExpenses
158168068 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-126710 USD
CY2021Q2 us-gaap Compensation Expense Excluding Cost Of Good And Service Sold
CompensationExpenseExcludingCostOfGoodAndServiceSold
105750 USD
CY2020Q2 us-gaap Compensation Expense Excluding Cost Of Good And Service Sold
CompensationExpenseExcludingCostOfGoodAndServiceSold
105173 USD
us-gaap Compensation Expense Excluding Cost Of Good And Service Sold
CompensationExpenseExcludingCostOfGoodAndServiceSold
211500 USD
us-gaap Compensation Expense Excluding Cost Of Good And Service Sold
CompensationExpenseExcludingCostOfGoodAndServiceSold
158114863 USD
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16565 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21537 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
55894 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
53205 USD
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
126710 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-122315 USD
us-gaap Net Income Loss
NetIncomeLoss
-267394 USD
us-gaap Net Income Loss
NetIncomeLoss
-158168068 USD
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29271755 shares
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15271755 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29271755 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15271402 shares
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.00
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.00
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-10.36
us-gaap Net Income Loss
NetIncomeLoss
-267394 USD
us-gaap Net Income Loss
NetIncomeLoss
-158168068 USD
bfnh Common And Preferred Stock Issued For Current Year Board Of Directors Compensation
CommonAndPreferredStockIssuedForCurrentYearBoardOfDirectorsCompensation
USD
bfnh Common And Preferred Stock Issued For Current Year Board Of Directors Compensation
CommonAndPreferredStockIssuedForCurrentYearBoardOfDirectorsCompensation
158000000 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
100 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-3047 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4058 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-10248 USD
us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
211500 USD
us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
114863 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-60052 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
47492 USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
47376 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
47492 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
47376 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-12560 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-13030 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39865 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52895 USD
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27305 USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39865 USD
us-gaap Interest Paid Net
InterestPaidNet
USD
us-gaap Interest Paid Net
InterestPaidNet
USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
USD
bfnh Common Stock Issued To Pay Accounts Payable Value
CommonStockIssuedToPayAccountsPayableValue
USD
bfnh Common Stock Issued To Pay Accounts Payable Value
CommonStockIssuedToPayAccountsPayableValue
1339 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
7289 USD
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29271755 shares
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29271755 shares
CY2021Q2 us-gaap Cost Of Revenue
CostOfRevenue
USD
us-gaap Cost Of Revenue
CostOfRevenue
USD
CY2021Q2 us-gaap Revenues
Revenues
USD
us-gaap Revenues
Revenues
USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-60406 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-627302 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
47308 USD
bfnh Common Stock Issued To Pay Accounts Payable
CommonStockIssuedToPayAccountsPayable
1339 USD
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
158000000 USD
us-gaap Net Income Loss
NetIncomeLoss
-158168068 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-119421 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-359908 USD
us-gaap Net Income Loss
NetIncomeLoss
-267394 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-627302 USD
CY2020Q2 bfnh Business Acquisition Equity Interests Purchased Number Of Shares
BusinessAcquisitionEquityInterestsPurchasedNumberOfShares
100000 shares
CY2020Q2 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
1000 USD
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:12pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">Use of Estimates</span></p> <p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:12pt; margin-bottom:0pt; ">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. </p>
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-504987 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-122315 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-126710 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-119421 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29271755 shares
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29271755 shares
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29271755 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29271755 shares
CY2020 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
1167 shares
CY2020 us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
1339 USD
CY2021Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.79
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares

Files In Submission

Name View Source Status
0001091818-21-000099-index-headers.html Edgar Link pending
0001091818-21-000099-index.html Edgar Link pending
0001091818-21-000099.txt Edgar Link pending
0001091818-21-000099-xbrl.zip Edgar Link pending
bfnh-20210630.xsd Edgar Link pending
bfnh-20210630_cal.xml Edgar Link unprocessable
bfnh-20210630_def.xml Edgar Link unprocessable
bfnh-20210630_lab.xml Edgar Link unprocessable
bfnh-20210630_pre.xml Edgar Link unprocessable
bfnh10q0621.htm Edgar Link pending
bfnh10q0621_htm.xml Edgar Link completed
bfnhlogo2019001.jpg Edgar Link pending
exhibit10-1.htm Edgar Link pending
exhibit31-1.htm Edgar Link pending
exhibit31-2.htm Edgar Link pending
exhibit32-1.htm Edgar Link pending
exhibit32-2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending